Atypical sideways recognition of CD1a by autoreactive γδ T cell receptors

Marcin Wegrecki1, Tonatiuh A. Ocampo2, Sachith D. Gunasinghe1,3, Anouk von Borstel1, Shin Yi Tin1, Josephine F. Reijneveld2,4, Thinh-Phat Cao1, Benjamin S. Gully1, Jérôme Le Nours1, D. Branch Moody2,6, Ildiko Van Rhijn2,4,6, Jamie Rossjohn1,5,6

CD1a is a monomorphic antigen-presenting molecule on dendritic cells that presents lipids to αβ T cells. Whether CD1a represents a ligand for other immune receptors remains unknown. Here we use CD1a tetramers to show that CD1a is a ligand for Vδ1+ γδ T cells. Functional studies suggest that two γδ T cell receptors (TCRs) bind CD1a in a lipid-independent manner. The crystal structures of three Vγ4Vδ1 TCR-CD1a-lipid complexes reveal that the γδ TCR binds at the extreme far side and parallel to the long axis of the β-sheet floor of CD1a’s antigen-binding cleft. Here, the γδ TCR co-recognises the CD1a heavy chain and β2 microglobulin in a manner that is distinct from all other previously observed γδ TCR docking modalities. The ‘sideways’ and lipid antigen independent mode of autoreactive CD1a recognition induces TCR clustering on the cell surface and proximal T cell signalling as measured by CD3ζ phosphorylation. In contrast with the ‘end to end’ binding of αβ TCRs that typically contact carried antigens, autoreactive γδ TCRs support geometrically diverse approaches to CD1a, as well as antigen independent recognition.
cells are subdivided into three main lineages based on the genes encoding their T cell antigen receptors (TCRs), namely, αβ, γδ and γδ T cells. αβ TCRs recognise antigens (Ags) encompassing peptides, lipids, and metabolites that are presented by Major Histocompatibility Complex (MHC), CD1 and MR1 molecules, respectively. The total α and γδ T cell pools in adult humans are both large in size, but studies of T cell-mediated immunity have mostly focused on αβ T cell recognition and activation. αβ TCRs bind to MHC, CD1, and MR1 with a conserved ‘end to end’ docking mode: the long axes of both proteins are aligned so that the membrane distal surface of the TCR contacts the membrane distal surface of the antigen presenting molecule(s). Although individual αβ TCRs show differential rotation or lateral translation on the surface of antigen presenting molecules, the ‘end to end’ approach means that they essentially bind atop of the Ag-binding cleft and in so doing contact exposed peptide antigen.

For γδ TCRs the number and nature of known antigenic targets continue to expand, and any general principles for the geometry of γδ TCR approach or conserved contact points on their targets are yet to be elucidated. For example, γδ TCRs can directly bind many cell surface and soluble proteins, including butyrophenols, ephrin type-A receptor 2 (EphA2), annexin A2, as well as MHC-I like molecules, such as endothelial protein C receptor (EPCR), T10, T22, MR1 and CD17-11. It was recently demonstrated that a population of γδ TCRs does not use the end to end mechanism and instead binds to the underside of MR1. Whether γδ TCRs can adopt unusual approaches to antigen-presenting molecules remains unknown.

Here we sought to understand if γδ T cells recognise the human CD1a protein, which is normally expressed at high density on Langerhans cells and myeloid dendritic cells. CD1 proteins bind and present lipids, including phospholipids, glycosphingolipids, lipopeptides, and apolar ‘headless’ lipids that function as antigens for T cells. Typically, the hydrophobic moieties of lipids are buried within the Ag-binding cleft of CD1, whereas polar moieties tend to protrude from the cleft and contact TCRs. Understanding the separate functions of the four human CD1 isoforms is important, because CD1a, CD1b, CD1c and CD1d all have differing patterns of expression in tissues, subcellular trafficking and three-dimensional architecture of the antigen-binding clefts. For example, while CD1c has an open, solvent-exposed antigen-binding cleft, CD1a possesses a binding cleft that is sequestered by the A’-roof of CD1a, which partially covers and shields the lipid from TCR contact. These differences result in isoform-related preferences in the repertoire of lipids that can be presented, as well as offer differing binding platforms for TCR recognition.

As contrasted with their roles in αβ T cell function, presently, our understanding of the extent to which CD1 family members represent ligands for γδ T cells is limited. CD1a-dependent activation of γδ T cells from lungs was seen in one study. Several tetramer studies showed that CD1b, CD1c, and CD1d bind bonafide γδ T cell ligands and two structural reports showed how Vδ1+ γδ TCRs bound over the CD1d-antigen binding cleft while co-contacting the exposed polar headgroup of the lipid antigen in an ‘end to end’ binding mode that is comparable to αβ TCR MHC docking. However, CD1a interactions with γδ TCRs have not been reported in part because CD1a presented Ags remain poorly understood, and no immunodominant antigens, equivalent to α-galactosyl ceramide for CD1d, were known.

Normally, antigens are needed for tetramer studies to achieve high avidity binding to TCRs. However, two recent studies show that CD1a carrying mixed endogenous lipids (CD1a-endo tetramers) could readily detect human αβ T cells without adding any defined antigens, bypassing a key technical barrier. Here, using the new approach of CD1a-endo tetramers, we discover autoreactive Vδ1+ γδ T cells that are restricted to CD1a. We show that Vγδ TCRs bind CD1a regardless of nature of the lipid bound, and that the unprecedented approach of Vδ1+ γδ TCR recognition, which contacts the backside of the CD1a binding cleft and β2 microglobulin, points to diverse modes of γδ TCR approach to targets.

**Results**

**Discovery of CD1a-specific γδ T cells.** While MHC tetramers require loading with a specific peptide to stain αβ T cells, CD1a-endo tetramers can permit binding to autoreactive αβ T cells without knowledge of the carried lipid. This approach allowed discovery of T cells that bind and recognise the membrane-distal roof domain of CD1a itself. We reasoned that this new tool might isolate autoreactive CD1a-restricted γδ T cells. To determine if CD1a-binding γδ T cells exist in humans, we first generated a γδ T cell line from peripheral blood mononuclear cells (PBMCs) from a healthy donor, CD3, by flow cytometric sorting of TCR γδ T cells and CD1a-endo tetramer+ T cells (Fig.1). In a different donor, CD22, γδ T cells were first enriched by magnetic sorting, followed by FACS sorting of CD1a-endotetramer+ cells (Fig.1b). In both cases, cells did not expand extensively in vitro, which is a known feature of human γδ T cells and the staining pattern clearly suggested the presence of CD1a-specific γδ T cells, and we could recover one TCRγ and one TCRδ sequence from each sort at the single cell level (Fig. 1c).

Although Vδ1+ γδ T cells are typically less abundant in blood than Vδ2+ γδ T cells, both CD3 and CD22 γδ TCRs used Vδ1 and varied in their Vγ chain usage. Transient transfection of the CO3 (Vγ4 Vδ1) and CO22 (Vγ2 Vδ1) γδ TCRs into HEK293T cells demonstrated that both γδ TCRs bound to CD1a-endotetramer, but not to CD1b-endo, CD1c-endo, or CD1d-endotetramers (Fig. 1c). CD1a is nearly non-polymorphic in humans, but the differential staining between the CO3 and CO22 γδ TCRs towards CD1a-endotetramer suggested that varied Vγ gene and CDR3 sequence could impact on CD1a-endo reactivity. Overall, these data demonstrate that autoreactive CD1a-specific γδ T cells exist, albeit at low frequency in the peripheral blood of healthy human subjects.

**TCR γ and δ chains co-recognise CD1a.** There are several reports of Vδ-chain dominance, particularly Vδ1, in the mechanism of target recognition by γδ T cells. To test whether the CO3 γδ TCR also depends on the Vδ chain for CD1a recognition, we replaced its Vγ4 chain with Vγ2, Vγ3, Vγ5, or Vγ9 chains from other γδ TCRs. We also used distinct Vγ4 chains from the CD1d-specific γδ TCR DP10.7 and the CD1b-specific γδ TCR BC14.1 and transiently transfected all hybrid γδ TCRs into HEK293T cells (Fig. 1d). Even though all the hybrid γδ TCRs were expressed at similarly high levels, only the native CO3 Vγ chain and the DP10.7 Vγ chain could support CD1a staining in combination with the CO3 Vδ chain. Of note, the BC14.1 Vγ chain, which did not support CD1a-endo staining, differs only in 3 amino acids from the CO3 Vγ chain, while the DP10.7 Vγ chain differs by only 2 amino acids, suggesting that tyrosine at position 104 (Tyr104) within the CDR3 loop is essential for CD1a-endo recognition. Replacement of the CO3 Vγ chain with the BC14.1 Vδ1 chain, did not lead to CD1a-endotetramer staining, suggesting that the CDR3 loop of the CO3 γδ TCR contributes to CD1a-endo binding. Accordingly, both γ and δ CO3 TCR chains are required for CD1a-endo binding and Tyr104 is apparently essential. Overall, evidence suggests that Vδ1 are most
γδ TCR binding to CD1a does not require specific lipid ligands. To understand the mechanism underpinning recognition of human CD1a by Vδ1+ γδ T cells we first expressed recombinant CO3 and CO22 γδ TCRs using a mammalian expression system, purified these γδ TCRs to homogeneity, and measured the affinity of the interaction towards CD1a-endo using surface plasmon resonance (SPR). The CO3 and CO22 γδ TCRs bound CD1a-endo with dissociation constant (K_D) of 23.6 ± 3.1 μM and 15.5 ± 0.5 μM, respectively (Fig. 2a, b). To our knowledge TCR cross-reactivity across other CD1 isoforms is undescribed. Nearly all previously identified TCRs are directed at the α1–α2 domains that show relatively low (<40%) amino acid sequence identity². However, α3 domains of CD1 proteins showed higher sequence similarity, and the CD1a-reactive CO22 γδ TCR showed weak but clearly detectable binding (K_D > 100 μM) to human CD1c (Supplementary Fig. S1a).
The cross-reactivity with CD1c provided the first hint of a non-canonical binding mode, which was tested further with sphingomyelin (SM) and sulfatide (SLF). Recent studies have shown that the headgroup of a very long chain C42 diene sphingomyelin (42:2 SM) protrudes from the membrane distal end of CD1a and broadly blocks polyclonal αβ TCRs in all donors tested. Sulfatide also acts at a known site on CD1a, where it blocks T cell response through local remodelling of a triad of residues on the membrane distal end of CD1a near the F’ portal. To determine the role of lipids in promoting and blocking the γδ TCR-CD1a interaction, we undertook affinity measurements using CD1a loaded with two known antigens, lyso-phosphatidylcholine (LPC) and diodeoxymycobactin lipopeptide (DDM). DDM is a CD1a-restricted lipopeptide derived from Mycobacterium tuberculosis, which protrudes from the F’ portal located on one side of CD1a and activates certain bacteria-specific T cell clones and can block activation of other autoreactive αβ T cell clones. In contrast to strong effects seen previously for αβ TCRs, 42:2 SM and SLF did not inhibit γδ TCR binding to CD1a.

**Fig. 2 CD1a binds γδ TCRs in vitro.** Surface plasmon resonance (SPR) sensorgrams and calculated binding curves for CO3 (a) and CO22 (b) γδ TCRs injected over a flow cell containing CD1a-endo. Comparison between HEK293S-cells produced (black) and refolded hybrid (red) TCR is shown for CO3 γδ TCR. c SPR data showing normalised binding curves between CD1a-endo (red curve) or loaded with different ligands (self-lipids: black symbols, DDM: green) to CO3 (top) and CO22 (bottom) γδ TCRs. The curves shown in a–c are representative of one experiment. Dissociation constants were calculated from two independent experiments (n = 2). For each concentration the points represent the mean and the error bars correspond to SD. d Engineered CD1a variants used to elucidate the binding determinants of the γδ TCRs. The side chains of mutated residues across the A’ roof (top) are shown in pink. The domain-swap chimeras (bottom) contain residues corresponding to human CD1c (CD1ca: navy blue) and human CD1d (CD1ad, light green). Light grey areas correspond to wild-type CD1a residues. The origin of the α domain in each construct is shown in the box diagram. e Dissociation constants of the binding between CO3 (left) or CO22 (right) γδ TCRs and wild-type CD1a (black), CD1a A’ roof mutants (pink), CD1ad (green), and CD1ca (navy blue) chimeric proteins were calculated from two independent experiments. The error bars correspond to SEM. Source data are provided as a Source Data file.
and 10–13 μM for CO3 and CO22 γδ TCRs, respectively), and the antigens LPC and DDM did not substantially augment binding to CD1a (Fig. 2c and Supplementary Table 1). Of interest, the binding of both γδ TCRs to CD1a-DDM showed a modest increase in affinity. For example, the CO3 γδ TCR binding towards CD1a-DDM was 9 μM versus 24 μM for CD1a-endo. Collectively, this suggested that autoreactive γδ TCRs are permissive to a wide range of lipid ligands for CD1a, including a SM ligand that broadly blocks αβ TCR binding.

**Mutational analysis of CD1a identifies differing effects on αβ and γδ TCRs.** The lack of a significant lipid-mediated blocking or augmenting effect on γδ TCR-CD1a binding suggested that the two CD1a-autoreactive γδ TCRs might follow the recently described pattern of a ‘lipid-agnostic’ CD1a recognition by autoreactive αβ T cells28,30. Here, many CD1a-restricted αβ T cells are thought to target the membrane distal end of CD1a, and that ‘end to end’ interactions of CD1a and TCR are abolished in the context of single and multiple mutations in the α1 and α2 helices of the heavy chain of CD1a, which constitute the membrane distal face of CD1a (Fig. 2d). To test γδ TCR recognition of the distal end of CD1a, we used a panel of CD1a A3-domain mutants and measured the affinity of interaction between CD1a-end and the two γδ TCRs. We previously found that triple mutants of the CD1a roof block binding of αβ TCRs without globally changing roof structures in ways that affect lipid binding28. Here we found that triple mutants across the A3-roof (ROO3A1: E62A, E65A, I72A; ROO3A2: I157A, T165A, R168A; and ROO4: E62A, E65A, T165A, R168A) were still recognised well by both γδ TCRs with affinities of 40 μM or higher (Fig. 2e and Supplementary Fig. S1b). Overall, our SPR-based analyses pointed towards a recognition mechanism by the autoreactive γδ TCRs that was largely independent both of lipids and the adjacent membrane distal surface of human CD1a, although moderate increase in affinity of autoreactive TCRs to DDM was observed.

The two γδ TCRs have a differing dependence on the CD1a A3-domain. Nearly all αβ and γδ TCRs bind ‘end to end’ with antigen presenting molecules, so that the TCR resides atop the αγ lipid and recognition of CD1a has not been previously studied. Thus, the antibody and α1-α2 domain independence could be explained if γδ TCRs bind CD1a, but do not bind on its membrane distal roof surface. The possibility of an alternative docking mode was supported by one recent study in which a subset of human γδ TCRs can directly recognise the α3 domain of MR1. To test whether the α3 domain of CD1a was recognised, we engineered chimeric CD1 proteins: CD1ad, carrying the α1 and α2 domains of CD1a and the α3 domain from human CD1d, as well as a CD1ca protein, with CD1c-derived α1 and α2 domains fused to the α3 domain of CD1a (Fig. 2d). SPR showed that the CO3 γδ TCR could recognise CD1ad (Kd = 16.1 ± 1 μM) but not the CD1ca protein, indicating that CD1a α1-α2 domains were essential and the CD1a α3 domain was dispensable for the CO3 γδ TCR interaction (Fig. 2e). However, the binding of the CO22 γδ TCR was impaired in the case of CD1ad and still detectable when recognising CD1ca (Kd > 100 μM) (Fig. 2e and Supplementary Fig. S1c). These data suggested that the CO22 γδ TCR and CO3 γδ TCR interacted with CD1a via different mechanisms, with the CO22 γδ TCR being dependent on the α3-domain, whereas the CO3 γδ TCR was not.

An unprecedented mode of γδ TCR recognition. To understand the molecular basis underpinning γδ TCR recognition of CD1a, we determined the crystal structure of the CO3 γδ TCR alone at 2.0 Å and in complex with CD1a-end, CD1a-sulfatide and CD1a-DDM to a resolution of 3.2 Å, 2.7 Å and 3.0 Å, respectively (Supplementary Table 2). Here, to crystallise these ternary structures, we engineered a hybrid TCR fusing the variable CO3 γδ domain to the constant TCR β domain and the variable CO38 domain to the constant TCR α domain, as done previously35,36. As shown by the SPR data, the resulting hybrid TCR bound human CD1a-end with an affinity value (Kd = 19 ± 0.3 μM) comparable to ‘wild-type’ CO3 γδ TCR (Kd = 23.6 ± 3.1 μM) (Fig. 2a). The crystal structure at the CO3 γδ TCR-CD1a interface was unambiguous, permitting a detailed analysis of the intermolecular contacts.

**The Vγ4 domain of the CO3 γδ TCR-CD1a-sulfatide complex revealed an unexpected mode of γδ TCR docking onto an antigen-presenting molecule (Fig. 3a).** Namely, the CO3 γδ TCR bound CD1a-β2 m heterodimer with an ‘end to side’ docking mode whereby the 87.4° incident angle is nearly perpendicular with CD1a. The TCR bound on the α1 side of the F’-pocket, where it also contacted β2-microglobulin but not the lipid ligand (Fig. 3a). This sideways docking mode differed substantially from the typical mechanism of αβ TCRs binding to MHC and MHC-I like molecules, as well as the two available CD1d- γδ TCR complex structures7,26, where ‘end to end’ docking occurs with the main axis of the TCRs showing an incident angle of 7–10° with the target protein and direct contact with the carried antigen (Fig. 3b)39. Moreover, the CO3 γδ TCR-CD1a docking mode was completely distinct from any γδ TCR complex structure previously reported, including the recently described Vβ1+ and Vβ3+ TCRs in complex with human MR115,37 (Fig. 3c). For MR1 the Vβ1+ γδ TCR sat underneath the antigen-binding cleft and contacted the α3-domain, whereas the Vβ3+ γδ TCR obliquely bound to the MR1 antigen-binding cleft. For CD1a, the striking features of the CO3 γδ TCR mode of contact are binding below the antigen display platform and the high incidence angle, which define a ‘sideways’ approach, as well as substantial contact with β2-microglobulin, rather than the α3 domain.

**γδ TCR co-recognises CD1a heavy chain and β2m.** While the Vγ4 domain of CO3 γδ TCR localised atop of the Ag-binding cleft, near the C-terminal end of the α1 helix of CD1a, the variable loops of the Vβ1 domain protruded into the cavity between CD1a-α1 and β2m creating an interface with the shape complementarity score of 0.74, indicating a very good fit (Fig. 4a). The total buried surface area (BSA) was 1320 Å2 (680 Å2 for CD1a and 640 Å2 for the TCR) (Fig. 4a), with CD1a contributing 70% and β2 m 30% to the total interface area. In agreement with chain swap experiments (Fig. 1d), both chains of the γδ TCR were involved in ternary complex formation with 40 and 60% contribution of the γ and δ chains, respectively (Fig. 4a). Here, the CDR16 and CDR3δ loops contributed 20 and 40% BSA to the interface, respectively while the CDR3γ loop contributed 6% (Fig. 4b). The additional 35% of the BSA was attributable to the framework region of the Vγ4 chain, which also agrees with chain swap data showing an essential role of Vγ4 in binding the CO3 γδ TCR (Fig. 1d), while the remaining variable loops (CDR2δ, CDR3δ, CDR4γ) were conserved between the two Vγ4 crystal structures7,26,39.
CDR1γ, and CDR2γ) were not involved in the interaction with CD1a (Fig. 4b).

A central focal point of the CO3 γδ TCR-CD1a-sulfatide complex is dominated by a short loop (residues 19–23) in the α1 domain of CD1a that makes extensive contacts (Supplementary Table 3) with the CO3 γδ TCR, whereby residues from the CDR3γ loop, framework residues from Vγ chain and the CDR3δ loop converged onto this CD1a recognition determinant (Fig. 4c). This short CD1a loop contains three aromatic residues that play a principal role in interacting with the CO3 γδ TCR. Namely, there were aromatic pi-stacking interactions between Tyr19 in CD1a and Trp99δ from the CDR3δ loop, with this aromatic cluster being extended by interactions between Trp23 from CD1a and Tyr104γ from the CDR3γ loop (Fig. 4c). The importance of this Trp23-Tyr104γ interaction seen in the three crystal structures was independently identified by the chain swap experiments, in which the only hybrid TCRs with tyrosine at this position were able to stain with CD1a tetramers (Fig. 1d). Moreover, His21 from CD1a made a series of van der Waals interactions with framework (FR) γ residues, Arg48γ, Tyr51γ and Glu62γ and Asp101δ from the CDR3δ loop (Fig. 4c). These germline-encoded framework residues are conserved across all the human TRGV genes except TRGV9, (Supplementary Fig. S3), potentially explaining why the TRGV9 TCR γ chain did not support CD1a binding (Fig. 1d). The contacts between CD1a and the CDR3δ loop were extended by a series of polar interactions, including hydrogen bonds of Glu96δ
and Asp101δ with Asn20 and Ser22 from CD1α, respectively, as well as main chain hydrogen bonding of residues 99–100 in the CDR3δ loop with Asn20 and Trp23 from CD1α, respectively (Fig. 4c).

Contacts with β2m were solely mediated by the Vδ chain, using the CDR1δ and CDR3δ loops (Fig. 4d). The contribution of the germline encoded Vδ1 residues involved Trp31δ from CDR1δ loop, which made extensive contacts with Asp35, Glu37 and Asn84 in β2m and corresponded to ~20% of BSA. These interactions were extended by the neighbouring CDR3δ loop, whereupon Arg98δ formed a salt bridge with Asp35, while Trp99δ formed a hydrogen bond to Asp35 from β2m (Fig. 4d). Accordingly, a series of germline-encoded and non-germline encoded regions of the CO3δγδ TCR underpinned this atypical sideways recognition mode with CD1α, which involved γδ TCR co-recognition of CD1α and β2m.

Antigen-independent binding of CD1α to a γδ TCR. To generate the CO3δγδ TCR-CD1α crystal structure, we used CD1α...
protein carrying heterogenous human embryonic kidney (HEK) cell-derived endogenous lipids (CD1a-endo) and were not able to unambiguously model lipid antigen in the CD1a cleft. However, the structure of the complex between the CO3 γδ TCR and CD1α-sulfatide, an endogenous lipid known to bind human CD1α,[23] showed a clear lipid density in the cleft of CD1a (Supplementary Fig. S4). The arrangement of the lipid chains highly resembled those observed in the CD1a-4:2 SM structure published recently,[29] where both lipid tails ran in parallel inside the A'-pocket (Supplementary Fig. S4b). The sulfatide headgroup protruded through the F'-portal and adopted a fixed position near the α2-helix of CD1α (Fig. 3a). Whereas sulfatide was previously shown to alter the distal surface of CD1α and protrude to block activation of αβ T cells by CD1α,[31] the location of the blocking headgroup for αβ T cells was 13 Å distant from the atypical CO3 γδ TCR binding site (Fig. 3a). The separate positioning of what are normally blocking headgroups on the 'top' of CD1α, versus the TCR contact site on the 'side' of CD1α, can explain why neither sulfatide nor 4:2 SM blocked CO3 γδ TCR binding to CD1α (Fig. 2c).

Given the large distance between the TCR docking site and the F'-portal, which is the site of antigen protrusion, we sought to understand why another well-known CD1α-restricted antigen, the M. tuberculosis-derived lipopeptide DDM, could increase the interaction between CO3 γδ TCR and CD1α (Fig. 2c). Accordingly, we solved the structure of the CO3 γδ TCR bound to CD1α carrying a new synthetic form of DDM that precisely matches the structure of natural DDM[40] (Fig. 5a), which showed a clear DDM ligand density in the CD1α cleft (Supplementary Fig. S4c). Similar to a prior structure of CD1α bound to a synthetic DDM-like molecule,[36] the C2α1 acyl tail of DDM anchored in the A' pocket. However, in contrast to CO3 γδ TCR-CD1α-sulfatide, the DDM lipopeptide head was enclosed almost entirely within the cleft, with the deoxyxynacbacic acid occupying the F'-portal and the deoxyxobactin moiety in the F'-portal (Fig. 5b). Although the DDM head group was distant from the TCR, its binding to CD1α induced notable rearrangement in the hydrophobic interior (Fig. 5c), where Phe144 in the α2-helix was pushed by the aryl ring of DDM towards Leu88 and Phe90, expanding the cleft and deforming the a1 domain of CD1α that shifted 3 Å towards the Vγ chain of CO3 (Fig. 5d). Consequently, the buried surface area between CD1α and the γ chain of CO3 increased from 290Å² (CD1α-sulfatide) to 390Å² (CD1α-DDM), and His86 in CD1α made additional hydrogen bond with the main chain of CO3 γδ (Fig. 5d). Accordingly, the DDM antigen can cause an induced fit change within the CD1α cleft, which translated into a change in the outer surface of CD1α that might explain the increase in binding affinity upon complex formation (Fig. 2c).

Energetic basis underpinning the CO3 γδ TCR-CD1α interaction. Given the unusual nature of the CO3 γδ TCR-CD1α complex, we next aimed to investigate the energetic basis underpinning this interaction. We generated additional alanine-scanning mutations on the CD1α-β2m heterodimer, which tested key candidate interactions identified by the crystal structure. These changes included six single site alanine mutations on the CD1α heavy chain (Tyr19, Asn20, His21, Ser22, Trp23, and His86) and three on β2m (Asp35, Glu37, Asn84). Then we assessed the impact of binding to the CO3 γδ TCR by SPR (Supplementary Fig. S5). The mutants were categorised as having no effect (green) if the Kd change was within 1 to 3-fold the WT value (29 µM), moderate effect (yellow) for the Kd change 3 to 5-fold, or strong effect (red) if the Kd value showed a >5-fold change (Fig. 6a). We found markedly decreased binding to CD1α mutants changed at the positions Tyr19, Asn20, Trp23 of CD1α and Asp35 of β2m (Supplementary Fig. S5). However, none of the point mutations completely disrupted binding. Therefore, we generated two triple mutants located near the proposed TCR contact sites, namely CD1α-LOOP3 (Tyr19, His21, Trp23) and β2m-TRIPLE (Asp35, Glu37, Asn84), both of which further reduced CO3 γδ TCR binding (Supplementary Fig. S5). Finally, a CD1α-β2m heterodimer carrying mutations at all 6 positions (CD1α-HEXA) did not detectably bind to CO3 γδ TCR (Supplementary Fig. S5). Overall, the binding data confirm that the interaction sites seen in crystal structures control the binding of CO3 γδ TCR to CD1α, whilst defining the particular residues within the CD1α 19-23 loop and the β2m chain that represent key energetic hot spots underpinning this interaction (Fig. 6b).

γδ TCR-CD1α binding induces TCR clustering and CD3ζ phosphorylation. We next investigated whether the atypical direction of TCR engagement led to T cell signal transduction. First, we stably expressed CO3 γδ TCR, CO22 γδ TCR and a positive control CD1α-autoreactive γδ TCR called BK6 in Jurkat76 cell lines.[40] As expected, co-culture with K562 cells expressing CD1α increased the frequency of Jurkat76.BK6 CD69+ cells. For the γδ TCRs, we noted a high background CD69 expression, and no clear increase after TCR transfer and CD1α+ cell addition (Supplementary Fig. S6a). This outcome was expected, in so far as human γδ T cells,[32] including MR1-reactive TCRs with unusual docking angles[8], expand or signal poorly ex vivo. In mice, hypo-responsive γδ TCR signalling pathways have been broadly observed in vivo,[41] where hypo-responsiveness protects against negative selection. However, for mouse γδ T cells proximal signalling via TCRζ is preserved in ways that allow maintenance of cells and expansion in immunosurveilience niches.[42] The alternative possibility is that the high incidence binding angles and 'head to side' interactions, might not lead to productive TCR clustering and signalling.

Therefore, we investigated TCR clustering using antibodies against CD3ζ subunits and CD3ζ phosphorylation upon exposure to CD1α. We exposed Jurkat cell lines to supported lipid bilayers containing either ICAM-1 only (negative control) or ICAM-1 and CD1α or anti-CD3/anti-CD28 antibodies that we used as a positive control. We analysed single-molecule images (Fig. 7a) and DBSCAN cluster maps (Fig. 7b, c). Unlike the pattern of CD69 expression, we observed significant increase in the density of TCR clusters for both αβ and γδ TCRs at rates similar to anti-CD3 antibody positive controls (Fig. 7c). Both unstimulated (ICAM-1 only) and stimulated (ICAM-1 and CD1α or anti-CD3/CD28) TCRs exhibited a non-random distribution on the cell membrane, as indicated by a significantly larger L(r)-r value relative to complete spatial randomness in Ripley's K analysis (Supplementary Fig. S6b). Further, L(r)-r values recorded for CD1α-binding induced clustering were larger than unstimulated TCRs but plateaued at a lower value than anti-CD3/CD28 stimulated TCRs. In addition, the CO22 γδ TCR showed larger TCR clusters after addition of CD1α. Thus, CD1α binding-induced spatial reorganisation of all CD1α-specific TCRs was prevalent irrespective of any geometric constraints imposed by docking topologies.

CD1α-induced phosphorylation of the CD3 signalling complex was examined by co-staining of anti-TCR with anti-pCD3ζ, which binds specifically to phosphorylated ITAM domain epitope Tyr142 in each CD3ζ chain. Cluster density increased significantly for the CO22 TCR after CD1α addition (Fig. 7d), and all three TCRs showed a significant ~two-fold increase in cluster size after adding CD1α or CD3/CD28. Combining the approaches to analyse TCR and pCD3ζ cluster colocalisation, a degree of colocalisation (DoC) score was implemented based an analysis
strategy known as combined cluster detection and colocalisation (Clus-DoC). In these experiments the DoC threshold for colocalisation was set to $\text{DoC} \geq 0.1$, above which the values represent colocalisation events captured between TCR and pCD3. Accordingly, nearly 20% of all TCR clusters showed a DoC score above the colocalisation threshold when triggered by CD1a binding (Fig. 7e). The fraction of TCRs colocalised with pCD3 are signalling competent and involved in T cell signal propagation. In previous work\textsuperscript{43}, densely packed TCR clusters were more signalling competent and involved in signal propagation. Of CD1a-specific TCRs examined here, CO22 forms the densest TCR clusters which is indicated by the highest number of TCR localisations in clusters (Fig. 7c) and the highest degree of colocalisation with pCD3 (Fig. 7e), suggesting higher signalling capacity for CO22 TCR compared to BK6 and CO3. Overall, despite unusual CO3 and CO22 $\gamma\delta$ TCR-CD1a docking.

Fig. 5 Interaction between CO3 $\gamma\delta$ TCR and CD1a carrying diverse lipid antigens. a Overview of CD1a-DDM-CO3 ternary structure shows the ligand orientation in the cleft of CD1a (lilac). DDM (magenta) fully occupies A' and F' pockets and does not significantly protrude through the F' portal of CD1a. b Relative position of the ligands in the cleft of CD1a bound to sulfatide (yellow) and DDM (magenta) in CD1a-CO3 ternary structures is shown. c Comparison of CD1a backbone in CO3-CD1a-sulfatide complex (light grey) and CO3-CD1a-DDM complex (lilac) shows that deoxymycobactic acid moiety of DDM (magenta) expands the F' pocket of CD1a by conformational changes of hydrophobic residues within the cleft of CD1a. d DDM-induced F' pocket expansion is associated with a 3 Å displacement of the CD1a-$\alpha_1$ helix towards the FR$\gamma$ region (green) of CO3 leading to a formation of an additional hydrogen bond (blue line) between CD1a-His86 and the main chain of CO3$\gamma$. 

\[ a \]
\[ b \]
\[ c \]
\[ d \]
contacting the carried antigen, the membrane distal end of the TCR typically docks ‘end to end’ on the α-helices at the membrane distal segment of the antigen presenting molecule.

Here we provide the first insights into γδ TCR recognition of CD1a, which along with other recently discovered γδ TCR targets, such as CD1b and MR1, now raise the basic questions about whether the ‘end to end’ mode of recognition used by γδ T cells generally applies to γδ T cells. The question also arises as to whether TCR recognition of proteins that are normally thought of as ‘antigen presenting molecules’ actually represent antigen presentation. Some CD1d-reactive γδ TCRs recognise glycolipids with a ternary ‘end to end’ interaction, leading to the idea that rearranged TCRs recognise normally diverse glycolipids. However, other CD1d reactive γδ TCRs do not require glycolipid antigen to be activated by CD1d. Furthermore, other γδ TCR targets like the EPCR, as well as butyrophilins, butyrophilin-like molecules, EphA2, annexin A2, and phycoerythrin are not known to present small carried antigens. Here we identify a γδ TCR target, CD1a, that is normally considered an antigen presenting molecule, yet does not function to display carried lipid antigen to the TCRs identified.

Four striking features of the mechanism identified here are the high TCR angle of incidence; the TCR contact site located below the antigen display platform; co-recognition of β2m; and low effects of lipid antigens and blockers on γδ TCR binding to CD1a. Thus, recognition of CD1a by the CO3 γδ TCR can be considered a sideways mechanism that functions outside the paradigmatic ‘end to end’ mode of recognition, and this mechanism does not represent lipid presentation. This conclusion is likely also true for CO22 γδ TCR, which although its ternary structure was not determined, binds CD1a in a lipid-independent, α3-domain dependent mechanism. We do acknowledge that the frequency of this unusual mechanism among γδ T cells is not yet known. However, very recent studies show that γδ TCR recognition of CD1b likewise does not require exogenous antigen. Also, recently identified MR1-reactive γδ TCRs do not require any carried antigens, and γδ TCRs were observed to bind underneath the antigen-binding platform of MR1, albeit in two orientations that are distinct from the β2-microglobulin dependent mechanism identified here.

More than 25 years ago, the Chien and Mariuzza groups pointed to structural elements in γδ TCRs that are more like immunoglobulins than αβ TCRs. Specifically, their work emphasised the structural resemblance between γδ TCR V domains and antibody V domains, as well as the long CDR3 lengths of γδ TCRs that match more closely to antibodies than to αβ TCRs and potentially offer more conformational flexibility. Our report identifies these and other immunoglobulin-like features of recognition of CD1a. The recognition determinant on CD1a for the CO3 γδ TCR rested principally on one loop, and in this regard the nature of the γδ TCR-CD1a interface, which was rich in aromatic residues and showed high shape complementarity, was reminiscent of antibody-antigen interactions. Further, the two TCR approaches to CD1a for CO3 and CO22 γδ TCRs are distinct from the docking geometries of the two known MR1-binding γδ TCRs. ‘End to end’ γδ TCR docking topologies with high angles of incidence on MHCI can lead to T cell signalling constraints, raising the question of whether sideways docking of γδ TCR on CD1a might be sterically feasible and lead to signalling via the CD3 complex. However, upon stimulation with membrane bound CD1a, both γδ TCRs formed signalling competent clusters on the surface of T cells and also induced phosphorylation of Tyr142 on CD3ζ subunit, similar to that of a canonical ‘end to end’ αβ TCR-CD1a engagement. These data rule out a fundamental physical block of clustering or other signalling incompatibility of sideways mode of TCR contact of CD1a.

**Fig. 6 Energetic landscape of CD1a-CO3 γδ TCR interaction.** a SPR was used to measure the binding affinity between CO3 γδ TCR and CD1a containing single or multiple mutations across the CO3-CD1a complex interface. Green (K_D change < 3-fold), orange (3 to 5-fold decrease in K_D) and red (>5-fold decrease in K_D) bars summarise the change in the binding affinities determined, binds CD1a in a lipid-independent, α3-domain dependent mechanism. The values were calculated from at least two independent experiments (n ≥ 2). The error bars correspond to SEM. b Residues involved in the CO3-CD1a complex formation on the surface of CD1a (dark grey)/β2m (blue) are coloured based on the mutation analysis shown in a. Amino acids critical for the recognition (red) by CO3 γδ TCR correspond to the Tyr19-Trp23 loop of CD1a. Source data are provided as a Source Data file.

**Discussion**

Whereas antibodies directly recognise diverse antigens, αβ TCRs co-recognise antigenic fragments that are co-presented on the membrane distal surface of antigen-presenting molecules. Key aspects of this T cell interaction model, whereby TCRs bind ‘end to end’ with antigen presenting molecules and the small antigens carried, apply also to CD1 and MR1, where αβ TCR-lipid-CD1 and αβ TCR-metabolite-MR1 are key mechanisms of recognition. Nevertheless, exceptions to this TCR co-recognition paradigm are emerging, as autoreactive TCRs restricted to CD1a and CD1c can directly contact the Ag-presenting molecules, while not co-contacting the carried lipid ligand. In previously studied examples, CD1c-restricted TCRs sat centrally atop the antigen-binding cleft, and only small, headless ligands allowed TCR binding as they were fully enclosed within CD1c. For CD1a, autoreactive TCRs bind in the ‘end to end’ manner but contact a large A’-roof structure on CD1a that is distinct from the protruding lipid headgroups. However, despite these fundamental differences in TCRs contacting or not
Instead, the pattern observed here, with intact proximal signalling events, is highly reminiscent of the main population of γδ T cells in mice that manifest constitutive clustering of their TCRs and CD3ζ phosphorylation, but not cytokine production or upregulation of activation markers. Recent studies show that for mice, such hypo-responsiveness appears to be intrinsic to the γδCD3 complex and is a very broad phenomenon when measured in vivo. Thus, mouse TCR hypo-responsiveness is increasingly viewed not as a defect of γδ T cell function, but instead as an adaptive response that confers protection against negative selection, which allows colonisation and survival in the skin and other immunoregulatory niches in response to ‘normality sensing’ of local self-ligands. Experimentally, human γδ T cells are difficult to expand ex vivo, and our TCR clustering and signalling data hint at a possible comparative hypo-responsiveness in the human system. Understanding this phenomenon could explain why human γδ T cells are difficult to capture and study in large numbers ex vivo despite their apparently high numbers in vivo.

Whether unusual γδ TCR docking modalities observed here, and in γδ TCR-MR1 setting, require other factors such as co-stimulatory molecules, remains to be determined. Moreover, how
sideways modes of CD1a recognition relate to geometric constraints within the immunological synapse remains unclear but may invoke increased membrane fluidity. Together, CD1a and MR1 reactive γδ TCRs support an evolving picture, whereby the docking geometries underpinning γδ TCR recognition can be vastly different to that of αβ TCR binding modes and another. Apparently, γδ TCRs are not locked into the familiar vertical approach to antigen presenting molecules, but perhaps resemble antibodies that can approach from any direction and latch onto any feature of an Ag-presenting molecule, or other structure-stress induced target receptor.

**Methods**

**T cells.** Human peripheral blood mononuclear cells (PBMCs) were obtained from de-identified, discarded leukoreduction collars provided by the Brigham and Women's Hospital Specimen Bank, as approved by the Partners Healthcare Institutional Review Board. γδ T cells were enriched using the untouched TCRγδ+ T cell isolation kit (Miltenyi Biotech).

**Recombinant proteins and tetramers.** Human CD1a, CD1b, CD1c, and CD1d monomers were obtained from the National Institute of Health (NIH) tetramer facility. For CD1a-endog., CD1b-endog, CD1c-endog, and CD1d-endog tetramers the monomers were used at 0.2 mg/ml in TBS and tetramerized. Synthetic deoxycytidine (3.0 µg) was dried in a 10 mm wide glass tube and dissolved in 6 ml dimethylsulfoxide (DMSO), followed by addition of 90 ml 20% CHAPS in Tris buffered saline and sonication for 1 h at 37 °C. After a short spin, 90 ml was transferred to a polypropylene vial, followed by 0.5 µg CD1a-endog and incubation for 2 h at 37 °C. Monomers were tetramerized using streptavidin-APC (Molecular Probes) or streptavidin-PE (Invitrogen).

**Staining and flow cytometry.** PBMCs, T cell lines and TCR-transfected cells were stained with tetramers at 2 µg/ml in phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.01% sodium azide. Cells and tetramer were incubated for 10 min at room temperature (RT), followed by addition of unlabeled anti CD3 monoclonal antibody (OKT3) to a final concentration of 2 µg/ml for 10 min at RT, followed by addition of labeled antibodies and another incubation for 10 min at RT, followed by 10 min at 4 °C. Cells were analysed by the BD LSR Fortessa flow cytometer and FlowJo software. Antibodies that were used: CD3- brilliant violet (BV)421 (UCHT1; BioLegend), CD3-Fluorescein isothiocyanate (FITC) (SK7; BD Biosciences), αγδ TCR-phycocerythrin (PE) or FITC (clone T08B9, BD Biosciences), γδ TCR-PE (B1, BioLegend).

**T cell lines.** For generation of T cell lines, cells were stained with CD1a-endog tetramer and antibodies or stained by using a BD FACSaria cell sorter. Expansion of sorted cells was performed by plating cells at 100–700 cells/well in round-bottom 96-well plates containing 2.5 × 10⁴ irradiated allogeneic PBMCs, 5 × 10⁵ irradiated Epstein-Barr Virus (EBV) -transformed Raji cells and 20 ng/ml anti-CD3 antibody (clone OKT3) per well. The next day human IL-2 or a mix of human IL-2, IL-7, and IL-15 was added to the wells. After 2 weeks, sorting and expansion procedure was repeated as needed.

For CD69 up-regulation and TCR clustering experiments we stably transduced CD1a-endo-restricted T cells from Jurkat76 cells using the lentiviral transduction system. OKT3) per well. The next day human IL-2 or a mix of human IL-2, IL-7, and IL-15 was added to the wells. After 2 weeks, sorting and expansion procedure was repeated as needed.

**For 2D-8F9 mep and TCR clustering experiments we stably transduced CD1a-endo-restricted T cells from Jurkat76 cells using the lentiviral transduction system.** Biotinylated or thrombin-cleaved CD1a was lipid loaded using lyso-PCMEM pH 6, 0.15 M ammonium sulfate, 15% PEG 4000. Crystals were cryoprotected overnight at 4 °C. The refolded samples were then dialysed three times against 10 mM Tris-HCl pH 8.5 over 24 h. CO3 γδ TCR and CO22 γδ TCR were both purified by DEAE cellulose and hydrophobic interaction followed by size exclusion chromatography for CO3 γδ TCR and anion exchange Mono Q for CO22 γδ TCR. The purity and quality of protein were analysed by SDS-PAGE.

**Surface plasmome resonance.** Biotinylated monomers of CD1a variants were coupled onto 5A Sensor Chips (Cytiva) to approximately 2500 response units per flow cell. Binding measurements were carried out in 2 × 40 ml 25 °C NaCl, 0.5% BSA buffer and consisted of serial injections of the analyte TCR to a maximum concentration of 50–100 µM. The data were analysed using Scrubber 2. The dissociation constant was calculated by fitting the binding response to a one site binding model in GraphPad.

**Crystallisation, data collection and structure determination.** CO3 γδ TCR alone crystallised in 0.1 M MES pH 6.15 ammonium sulfate, 15% PEG4000 and diffracted to 2.0 Å at the MX2 beamline (Australian Synchrotron). Upon data processing in XDS and CCP4, the structure was solved by molecular replacement in phenoX Phaser, using BK6 αβ TCR structure (PDB 4X6B) as search model. The complete hybrid TCR model was generated using the AutoBuild module from Phenix and was further refined by combining automated and manual refinement cycles in CNS and COOT, respectively, until the final Rfree/Rwork of 20.2%/25.4% was reached. CO3 and CD1a-endog were mixed at 1:1 molar ratio and incubated at 4 °C overnight to allow complex formation. Teritary complex crystals appeared after 3–4 days in 20% PEG 3350, 0.2 M ammonium sulphate or 0.1 M MES pH 6, 0.15 M ammonium sulfate, 15% PEG 4000. Crystals were cryoprotected in 12% (v/v) well solution supplemented with 20% glycerol or 10% ethylene glycol and flash frozen in liquid nitrogen. CO3 γδ TCR-CD1a-endog crystals diffracted to 3.2 Å at the MX2 beamline (Australian Synchrotron). The crystals of CO3 γδ TCR-CD1a-endog and CO3 γδ TCR-CD1a-DDM were obtained in the same condition using CO3-CD1a-endog crystals as seeds and were diffracted at the MX2 beamline (Australian Synchrotron) to 2.7 Å and 3.0 Å respectively. Data processing was performed in XDS and CCP4. The structure of CO3 γδ TCR-CD1a-endog was solved by molecular replacement using a CD1a binary structure (PDB 7WKP) and the CO3 γδ TCR alone as search models. The resulting ternary model was used in the molecular replacement search for CO3 γδ TCR-CD1a-sulfate and CO3 γδ TCR-CD1-DDM complexes. The constant domains of CO3 γδ TCR were highly disordered in the CO3-CD1-endog complex and could be only partially traced, however, the electron density map was significantly improved in the CO3-CD1a-endog complexes. The equivalent chain orientations were used to mask the CO3-CD1-endog complex for electron density calculations with the same cell parameters. Full length γδ TCR and CD1-a chains separated by self-cleaving 2 A peptide were purchased from GENERIWIZ and cloned into a (MSCV)-IRES- GFP (pMIG) vector. All plasmids used for transfection were purified using a QiAprep Spin Miniprep Kit (QIAGEN) or NucleoBond Xtra Midi EFi kit (Machery-Nagel). HEK293T cells were co-transfected with pMIG-TCR and pMIG-CD3γδ, δ, ε, and γ using FuGENE-6 (Promega) (51). Expression of TCR and CD3 and binding of tetramer was analysed using the BD LSFR cytoometer and BD FACSuite 10.8.1; Treestar & BD Biosciences. For replacement of TCR γ gene segments, full length TCR γ gene segments were purchased from GENERIWIZ and used to replace the γ chain of the CO3 TCR in the plasmid (MSCV)-IRES- GFP (pMIG) using EcoRI and BsaEI restriction enzymes.

**Protein production, purification and lipid loading.** Human CD1a, CD1a mutants, CD1b, CD1c, and CD1d chimeric proteins were expressed in HEK293 cells and purified by nickel-affinity followed by size exclusion chromatography. Proteins used in surface plasmome resonance experiments were biotinylated on their C-terminus using BirA ligase. CD1a used in crystallisation trials was treated with thrombin to remove fos-jun zippers, Avi and His-tags and further de-glycosylated by incubating with endoglycosidase H (NEB) at RT overnight. Biotinylated or thrombin-cleaved CD1a was lipid loaded using lysophosphatidylcholine (Avanti) and phospholipids (Avanti; 13:0, 15:0, 16:0, 18:0, 20:4). For CD1b, CD1c, CD1d, and CD1 chimeric proteins were expressed in E. coli and purified by nickel-affinity followed by size exclusion chromatography run on Superdex200 column (GE Healthcare).

Wild-type extracellular domain of the CO3 γδ TCR was expressed in HEK 293 S cells with 3 C promote-cleavable fos-jun zippers followed by a His-tag at the carboxy terminus and purified via Ni-NTA and size exclusion chromatography. The CO3 and CD22 hybrid γδ TCRs were expressed as separate α and β chains in BL21 E. coli cells cotransfected with inclusion bodies and solubilised in buffer containing 8 M Urea, 20 ml Tris-HCl pH 8.0, 0.2 M PMSF, 0.5 M Na-EDTA and 1 mM DTT. The solubilized TCR chains were refolded at a 1:1 ratio in buffer with 5 M Urea, 600 µL Arginine-HCl 100 mM Tris-HCl pH 8.5, 2 µM Na-EDTA, 0.2 µM PMSF, 0.5 mM oxidised glutathione and 5 mM reduced glutathione overnight at 4 °C. The refolded samples were then dialysed three times against 10 mM Tris-HCl pH 8.5 over 24 h. CO3 γδ TCR and CO22 γδ TCR were both purified by DEAE cellulose and hydrophobic interaction followed by size exclusion chromatography for CO3 γδ TCR and anion exchange Mono Q for CO22 γδ TCR. The purity and quality of protein were analysed by SDS-PAGE.

**Surfcmol xray**
DDM and CO3-CD1a-sulfatide complexes allowing for both constant domains to be built. The final models were obtained by refinement cycles in phenix.refine and Coot software. Structures were checked with MIRTools (23/29, 23/27 A for CO3-CD1a-end, CO3-CD1a-sulfate and CO3-CD1a-DMX respectively. The quality of the data was validated by Research Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation and Deposition Services website. Contact residues and complementarity score were calculated in CCP4, buried surface area analyses and graphics were undertaken in UCSF Chimera.72

T cells activation assays and flow cytometry. Approximately 1 x 10^6 Jurkat cells expressing the TCRs of interest were seeded per well of a 96-well round-bottom plate. To check the up-regulation of CD69, the Jurkat cells were co-cultured for 16 h with CD3/CD28 dynabeads (Gibco) or CellTrace Viole (cat. no. C34571, Thermo-Fisher Scientific, MA, USA) labelled parental K562 (CD1a+) or CD1a-expressing K562 (CD1a-). Cells were labelled with 200 M Trasylol (Roche) and 222727 for CO3-CD1a-end, CO3-CD1a-sulfate and CO3-CD1a-DMX respectively. The quality of the data was validated by Research Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation and Deposition Services website. Contact residues and complementarity score were calculated in CCP4, buried surface area analyses and graphics were undertaken in UCSF Chimera.72

Preparation of supported lipid bilayer (SLB). Glass coverslips of 0.17 mm thickness were thoroughly cleaned with 1 M KOH and rinsed with Milli-Q water and placed in 100% ethanol prior to drying inside a fume hood. Following plasma cleaning, glass coverslips were adhered to eight-well silicone chambers (Ibidi, #80841). SLB was prepared by vesicle extrusion of 1 mg/ml liposome solution.80 The lipid composition of liposomes include 96.5% DOPC (1,2-dioleoyl-sn-glycerol-3-phosphocholine), 2% DGS-NTA(Ni) (1,2-dioleoyl-sn-glycerol-3-[N-(5-amino-1-carboxypentyl)-iminodiacetic acid]succinyl] (nickel salt), 1% Biotinyl-Cap-PE (1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine-N-(cap biotinyl) (sodium salt)), and 0.5% PEG5000-PE (1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N[ methoxy(poly-ethyene glycol)]-5000) (ammonium salt) (mol%) all available from Avanti Polar Lipids (DOPC, 850375 C), (DGS-NTA(Ni), 790404 C), (Biotinyl-Cap-PE, 807273 C), (PEG5000-PE, 808220 C). Extruded liposomes were added to eight-well chambers at a ratio of 1.5 with Milli-Q water (10 mM CaCl2) and incubated for 30 min at RT before gently rinsing with TBS repeatedly. By retaining ~20 µl of TBS in each well, disruption to SLB was minimised during washing steps. Fluorescence recovery after photobleaching (FRAP) was used to examine the lateral mobility of freshly prepared SLB by adding fluorescein streptavidin (Invitrogen, #S12238). Excess Ca2+ ions on SLB were removed with 0.5 mM EDTA, followed by gentle rinsing with Milli-Q water. The functionalised NTA groups in DGS-NTA(Ni) lipids were recharged by adding 1 mM NiCl2 solution to SLB for 15 min. Excess Ni2+ ions were removed by repeated washing with TBS.

Stimulation and immunomunostaining of T cells on SLB. The functionalised biotin groups on SLB were coupled to 100 µg/ml streptavidin (Invitrogen, #A27031) followed by a second coupling to 200 ng/ml of His-tagged ICAM-1 (Sino Biological, #10346-H08H). SLB was functionalised with biotinylated anti-CD3 (Invitrogen, #13-0037-82) and anti-CD28 monoclonal antibodies (Invitrogen, #13-0289-82). NTA functionalised lipids were coupled with 0.5% PEG5000-PE (1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N[ methoxy(poly-ethyene glycol)]-5000) (ammonium salt) (mol%) all available from Avanti Polar Lipids (DOPC, 850375 C), (DGS-NTA(Ni), 790404 C), (Biotinyl-Cap-PE, 807273 C), (PEG5000-PE, 808220 C). Extruded liposomes were added to eight-well chambers at a ratio of 1.5 with Milli-Q water (10 mM CaCl2) and incubated for 30 min at RT before gently rinsing with TBS repeatedly. By retaining ~20 µl of TBS in each well, disruption to SLB was minimised during washing steps. Fluorescence recovery after photobleaching (FRAP) was used to examine the lateral mobility of freshly prepared SLB by adding fluorescein streptavidin (Invitrogen, #S12238). Excess Ca2+ ions on SLB were removed with 0.5 mM EDTA, followed by gentle rinsing with Milli-Q water. The functionalised NTA groups in DGS-NTA(Ni) lipids were recharged by adding 1 mM NiCl2 solution to SLB for 15 min. Excess Ni2+ ions were removed by repeated washing with TBS.

Single-molecule imaging with direct stochastic optical reconstruction microscopy (dSTORM). Imaging buffer consisting of TN buffer (50 mM Tris-HCl pH 8.0, 10 mM NaCl), oxygen scavenger system GLOX [0.5 mg/ml glucose oxidase (Sigma– Aldrich, #G21233); 40 mg/ml catalase (Sigma– Aldrich, #C–100); and 10% w/v glucose], and 10 mM 2-aminoethanol (MEA; Sigma– Aldrich, #M6500) was used for single-molecule imaging with dSTORM. Image sequences for dSTORM were acquired on a total internal reflection fluorescence (TIRF) microscope (Nanoimager by ONI) equipped with a 100x (1.4 NA) oil immersion objective, XYZ closed-loop piezo stage, and lasers 405 nm (150 mW), 473 nm (1 W), 561 nm (1 W) and 640 nm (1 W) at 30 °C. Time series of 10,000 frames were acquired per sample, per channel (640 or 561 nm laser channel) with an exposure time of 30 ms, at near-TIRF angle of 54°. For dual-colour acquisition, higher wavelength channel (640 nm laser for Alexa Fluor 647) was acquired first, followed by the channel with shorter wavelength (561 nm laser for Alexa Fluor 568) using a sCMOS camera (ORCA Flash 4, Hamamatsu). Image processing, including fiducial markers-based drift correction, two-channel alignment, and generation of x-y particle coordinates for each localisation was carried out by ONI proprietary software (version 1.16).

Ripley’s K analysis. To perform Ripley’s K analysis on single-molecule images43 we used the linearised form of Ripley’s (K) defined as L(r) = r – r0, where r is the spatial scale radius. While in complete spatial randomness L(r) = r0, a positive or negative value for L(r) – r0 can indicate clustered or dispersed localisations respectively58. For each localisation, Ripley’s (K) calculates the number of neighbouring localisations within a given radius (r) corrected by the total density of localisations. The start (0, end (100 nm), and step size (10 nm) for r in the algorithm were user defined.

Cluster analysis of single-molecule images. For quantification of cluster parameters in single-molecule images, we used a custom-build algorithm59 that utilises a density-based spatial clustering with noise (DBSCAN) analysis implemented in MATLAB to quantify individual clusters. Here, we pre-determine the minimum number of neighbours (minimum points = 3) and the radius which they occupy (r = 20 nm). The combined cluster detection and colocalisation (Clus-DoC) analysis was performed to quantify both spatial distribution and the degree of colocalization of two proteins/receptors59. This analysis relies on generating density gradients for each individual localisation by calculating the number of molecules captured from both channels with increasing circle radius (r = 20 nm). These density gradients are then normalised to the density at the maximum radius respectively for channel 1 and channel 2. The resulting two types of distributions generated for each channel were then compared by calculating the rank correlation coefficient using Spearman correlation where the local coefficient was measured by a value proportional to the distance of the nearest neighbour. Accordingly, each localisation was assigned with a DoC score ranging from +1 (indicating colocalization) to –1 (indicating segregation) with 0 indicating random distribution. As previously described59, the threshold for DoC is a user-defined variable and can be optimised to different experimental conditions. Hence, the DoC threshold for colocalisation was set to DoC 2.0, above which the variables represent colocalization events captured between the two channels.

Statistical analyses. When comparing multiple groups, the statistical analysis was performed using one-way ANOVA in GraphPad Prism software (version 9.3.1). Statistical significance reported by P-values indicated as ns (no significance); *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. Error bars represent the SEM.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The structure factors and PDB coordinates of the crystal structures generated in this study have been deposited in the RCSB Protein Data Bank under the following accession codes: 7RYL, (CO3 binary); 7RYM, (CO3-CD1a-end); 7RNY, (CO3-CD1a-sulfatide); 7RYG, (CO3-CD1a-DDM). The structural data used for molecular replacement in this study are available in the RCSB Protein Data Bank under accession codes 436B and 7KPI. The surface plasmon resonance binding data generated in this study are provided in the Source Data file. T cell activation data and single cell image analyses are provided in the Source Data file. Source data are provided with this paper.

Code availability. The link to custom-build cluster analysis algorithm used in this study is available at GitHub repository link (https://github.com/PRNivocich/ClusDoC) which was previously published59.

Received: 15 September 2021; Accepted: 16 June 2022; Published online: 05 July 2022

References. 1. Morrissey, K. A. et al. The molecular architecture of the marsupial gammamu T cell receptor defines a third T cell lineage. Science 371, 1383–1388 (2021).
2. Ripley, S. J., et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33, 169–200 (2015).
3. Borg, N. A. et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T cell receptor. Nature 448, 44–49 (2007).

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-31443-9 | www.nature.com/naturecommunications
4. Garboci, D. N. et al. Structure of the complex between human T cell receptor, viral peptide and HLA-A2. Nature 384, 134–141 (1996).

5. Garcia, K. C. et al. An alpha/beta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science (New York, N.Y.) 274, 209–219 (1996).

6. Willcox, B. E. & Willcox, C. R. y8 TCR ligands: the quest to solve a 500-million-year-old mystery. Nat. Immunol. 20, 121–128 (2019).

7. Uritani, A. et al. B-1 lipoprotein antigen recognition by the gammadelta T cell. Nat. Immunol. 14, 1137–1145 (2013).

8. Le Nours, J. et al. A class of gammadelta T cell receptors recognize the underside of the antigen-presenting molecule MR1. Science 366, 1522–1527 (2019).

9. Adams, E. J. & Luoma, A. M. The adaptable major histocompatibility complex (MHC) fold structure and function of nonclassical and MHC class I-like molecules. Annu. Rev. Immunol. 31, 529–561 (2013).

10. Harly, C. et al. Human y8 T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2. Sci. Immunol. 6 (2021).

11. Willcox, C. R. et al. Cytomegalovirus and tumor stress surveillance by binding with HLA-B27. Proc. Natl Acad. Sci. USA 118, e210288118 (2021).

12. Willcox, C. R. et al. Butyrophilin-like 3 directly binds a human Vγ4(+) T cell receptor using a modality distinct from clonally-restricted antigen. Immunity 51, 813–825.e814 (2019).

13. Van Rhijn, I., Godfrey, D. I., Rossjohn, J. & Moody, D. B. Lipid and small-molecule display by CD1 and MR1. Proc. Natl Acad. Sci. USA 115, 80–87 (2014).

14. Zajonc, D. M. et al. Understanding the drivers of MHC restriction of T cell receptors. Nat. Rev. Immunol. 18, 467–478 (2018).

15. Young, D. C. et al. Synthesis of dideoxymycobactin antigens presented by CD1d. Proc. Natl Acad. Sci. USA 111, 24208–24213 (2014).

16. La Gruta, N. L., Gras, S., Daley, S. R., Thomas, P. G. & Rossjohn, J. Understanding the drivers of MHC restriction of T cell receptors. Nat. Rev. Immunol. 15, 80–87 (2014).

17. Reijneveld, J. F. et al. Human γδ T cells recognize CD1b by two independent mechanisms. Proc. Natl Acad. Sci. USA 113, 9370–9375 (2016).

18. Rice, M. T. et al. Recognition of the antigen-presenting molecule MR1 by a Vδ1δ3(+)/CD1d(+) gammadelta T cell receptor. Proc. Natl Acad. Sci. USA 118, e210288118 (2021).

19. La Gruta, N. L., Gras, S., Daley, S. R., Thomas, P. G. & Rossjohn, J. Understanding the drivers of MHC restriction of T cell receptors. Nat. Rev. Immunol. 18, 467–478 (2018).

20. Young, D. C. et al. Synthesis of dideoxymycobactin antigens presented by CD1d reveals T cell fine specificity for natural lipidic structure. J. Biol. Chem. 284, 25087–25096 (2009).

21. Wencker, M. et al. Inmate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness. Nat. Immunol. 15, 80–87 (2014).

22. McKinzie, D. R. et al. Normality sensing licenses local T cells for innate-like tissue surveillance. Nat. Immunol. 23, 411–422 (2022).

23. Zeng, X. et al. yδ T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response. Immunity 37, 524–534 (2012).

24. Li, H. et al. Structure of the Vδ domain of a human gammadelta T-cell antigen receptor. Nature 391, 502–506 (1998).

25. Rock, E. P., Sibbald, P. R., Davis, M. M. & Chien, Y. H. CD3δ length in antigen-specific immune receptors. J. Exp. Med. 179, 323–328 (1994).

26. Zareie, P. et al. Canonical T cell receptor docking on peptide-MHC is essential for T cell signaling. Science 327, 629–634 (2012).

27. Singh, N. K. et al. An engineered T cell receptor variant realizes the limits of functional binding modes. Biochemistry 59, 4163–4175 (2020).

28. Saito, S. D. et al. Human CD1b with bound ligands at 2.3 A, a view into the TCR-MHC complex. Science (New York, N.Y.) 274, 209–219 (1996).

29. Zajonc, D. M. et al. CD1d-lipid antigen presentation and T cell function. Annu. Rev. Immunol. 22, 817–890 (2004).

30. Gadola, S. D. et al. Structure of human CD1b with bound ligands at 2.3 A, a maze for alkyl chains. Nat. Immunol. 3, 721–726 (2002).

31. Giubbia, B. et al. Crystal structure of mouse CD1d bound to the self ligand phosphatidylinositol: a molecular basis for NK cell activation. J. Immunol. 170, 977–984 (2003).

32. Scharf, L. et al. The 2.5 A structure of CD1c in complex with a mycobacterial lipid reveals an open groove ideally suited for diverse antigen presentation. Immunity 33, 853–862 (2010).

33. Zajonc, D. M., Elsässer, M. A., Teyton, L. & Wilson, I. A. Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat. Immunol. 4, 808–815 (2003).

34. Agea, E. et al. Human CD1-restricted T cell recognition of lipids from pollens. J. Immunol. 172, 934–941 (2004).

35. Reinelevéd, J. F. et al. Human γδ T cells recognize CD1b by two distinct mechanisms. Proc. Natl Acad. Sci. USA 117, 22944–22952 (2020).

36. Roy, S. et al. Molecular Analysis of Lipid- Reactive Vδ1δ3 gammadelta T Cells Identifiable by CD1c T cell receptor. J. Immunol. 196, 1933–1942 (2016).

37. Luoma, A. M. et al. Crystal structure of Vδ1δ3 T cell receptor complex in common with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human gammadelta T cells. Immunity 39, 1032–1042 (2013).

38. Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science (New York, N.Y.) 274, 94–96 (1996).

39. Cotton, R. N. et al. Human skin is colonized by T cells that recognize CD1a independently of lipid. J. Clin. Invest. 131, e460706 (2021).

40. Cotton, R. N. et al. CD1a selectively captures endogenous cellular lipids that broadly block T cell response. J. Exp. Med. 218, e20202699 (2021).

41. Birkenshaw, R. W. et al. alphabeta T cell antigen receptor recognition of CD1d-presenting self lipid ligands. Nat. Immunol. 16, 238–246 (2015).

42. de Jong, A. et al. CD1a-autoreactive T cells recognize natural skin oils that function as headless antigens. Nat. Immunol. 15, 177–185 (2014).

43. Spada, F. M. et al. Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J. Exp. Med. 191, 937–948 (2000).

44. Adams, E. J., Chien, Y. H. & Garcia, K. C. Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. Science 308, 227–231 (2005).

45. Reinelevéd, J. F. et al. Human gammadelta T cells recognize CD1b by two distinct mechanisms. Proc. Natl Acad. Sci. USA 117, 22944–22952 (2020).

46. Moody, D. B. B. et al. T cell activation by lipopeptide antigens. Science 303, 527–531 (2004).

47. Zajonc, D. M. et al. Molecular mechanism of lipopeptide presentation by CD1a. Immunity 22, 209–219 (2005).

48. Rice, M. T. et al. Recognition of the antigen-presenting molecule MR1 by a Vδ1δ3(+) gammadelta T cell receptor. Proc. Natl Acad. Sci. USA 118, e210288118 (2021).

49. Willcox, C. R. et al. The authors declare no competing interests.
